Publications
133
Citations
2,641
Est. group size
~17
Recurring co-author estimate
Active years
17
Publishing since 2009
Erin M. Bertino's work centers on clinical trials for non-small cell and small cell lung cancer, focusing on targeted therapies that address specific genetic mutations (such as EGFR, ALK, BRAF, and HER2 alterations) as well as combination treatments involving immunotherapy and chemotherapy. This research aims to improve treatment options for patients with advanced or metastatic lung cancer, including cases where the disease has spread to the brain, and to understand how tumors develop resistance to targeted drugs.
Publication output has fluctuated over the last decade with peaks in 2019, 2021, and 2023, but has notably declined in 2024-2025 compared to prior years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network · 2024
- CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network · 2024
- Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
2023
- Podcast on the Management of Adverse Events Associated with Lorlatinib
Advances in Therapy · 2022
- Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA
Lung Cancer · 2022
- Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib.
Journal of Clinical Oncology · 2022
- Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Clinical Cancer Research · 2020
- Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced<i>EGFR</i>-Mutant Non–Small Cell Lung Cancer
JAMA Oncology · 2019
- Journal of Thoracic Oncology×18
- Journal of Clinical Oncology×15
- Annals of Oncology×8
- Lung Cancer×5
- International Journal of Radiation Oncology*Biology*Physics×5
- Shadia I. Jalal
Medicine · Indiana University
- Hossein Borghaei
Medicine · The Ohio State University
- David P. Carbone
Medicine · The Ohio State University
- Gregory A. Otterson
Medicine · The Ohio State University
- Tamio Okimoto
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile